Ｍ－ＳＯＳＥＩ（4565）　Sosei Regains Worldwide Rights from Teva to Develop and Commercialize Novel Small Molecule CGRP Antagonists for Migraine and Other Severe Headache 2018/03/13
/-
読み込み中…